Evidence map›Paper›PMID 33912835›Full record

ArticleCritical care explorations2021

Hemodynamic Effects of an Increased Midodrine Dosing Frequency.

Shea A Macielak, Nicholas J Vollmer, Natalie A Haddad, Christoph G S Nabzdyk, Scott D Nei

Open access · goldAbstract read
In one paragraph

Article in Critical care explorations, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Midodrine use in critically ill patients: a narrative review.Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2022
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Shea A MacielakDepartment of Pharmacy, Mayo Clinic, Rochester, MN.
Nicholas J VollmerDepartment of Pharmacy, Mayo Clinic, Rochester, MN.
Natalie A HaddadDepartment of Pharmacy, Mayo Clinic, Rochester, MN.
Christoph G S NabzdykDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN.
Scott D NeiDepartment of Pharmacy, Mayo Clinic, Rochester, MN.
Mayo Clinic in Arizona · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In practice, midodrine has been used to reduce IV vasopressor requirements and decrease ICU length of stay. However, recent publications have failed to show clinical success when midodrine was administered every 8 hours. One possible reason for the lack of clinical efficacy at this dosing interval may be the pharmacokinetic properties of midodrine that support a more frequent dosing interval. Here, we report our institutional experience with midodrine at a dosing frequency of every 6 hours.

designSingle, quaternary academic medical center, retrospective, descriptive study.

settingFloor and ICU patients admitted to Mayo Clinic, Rochester, from May 7, 2018, to September 30, 2020. PATIENTS: Adult patients with an order for midodrine with a dosing frequency of "every 6 hours" or "four times daily" were eligible for inclusion.

interventionsNo intervention performed. All data were abstracted retrospectively from the electronic medical record. MEASUREMENTS AND MAIN

resultsForty-four unique patients were identified that met inclusion criteria. Patients were an average of 65 years and 63.6% were male. The individual doses of midodrine ranged from 5 to 20 mg. Twenty-three patients (52.3%) were receiving IV vasopressors at the time midodrine was ordered every 6 hours. Vasopressor requirements decreased from an average of 0.10 norepinephrine equivalents 24 hours prior to the every 6-hour order to 0.05 norepinephrine equivalents 24 hours after an order for midodrine every 6 hour was placed.

conclusionsIncreasing the dosing frequency of midodrine to every 6 hours may optimize its pharmacokinetic profile without compromising safety. This midodrine dosing frequency should be prospectively evaluated as a primary strategy for accelerated IV vasopressor wean.

Indexed as

hemodynamicsintensive caremidodrinepharmacokineticsvasopressors

Identifiers

PMID33912835
PMCPMC8078337
OpenAlexW3157380207

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.